USD 3.22
(-5.26%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | -6.65 Million USD | -307.33% |
2022 | 3.2 Million USD | -90.56% |
2021 | 33.97 Million USD | 1157.25% |
2020 | 2.7 Million USD | 62.18% |
2019 | 1.66 Million USD | -68.7% |
2018 | 5.32 Million USD | 0.0% |
2017 | - USD | 0.0% |
2016 | - USD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | - USD | 100.0% |
2024 Q2 | - USD | 0.0% |
2023 Q3 | - USD | -100.0% |
2023 Q4 | -14.66 Million USD | 0.0% |
2023 Q1 | 802 Thousand USD | 0.0% |
2023 FY | 1.15 Million USD | -63.97% |
2023 Q2 | 354 Thousand USD | -55.86% |
2022 Q1 | 802 Thousand USD | 0.0% |
2022 Q4 | 802 Thousand USD | 0.0% |
2022 Q2 | 802 Thousand USD | 0.0% |
2022 Q3 | 802 Thousand USD | 0.0% |
2022 FY | 3.2 Million USD | -90.56% |
2021 Q2 | 2.18 Million USD | -92.54% |
2021 FY | 33.97 Million USD | 1157.25% |
2021 Q1 | 29.3 Million USD | 2890.31% |
2021 Q4 | 802 Thousand USD | -52.18% |
2021 Q3 | 1.67 Million USD | -23.32% |
2020 Q4 | 980 Thousand USD | 72.84% |
2020 FY | 2.7 Million USD | 62.18% |
2020 Q2 | 567 Thousand USD | -3.57% |
2020 Q1 | 588 Thousand USD | 4.44% |
2020 Q3 | 567 Thousand USD | 0.0% |
2019 Q3 | 441 Thousand USD | 12.5% |
2019 Q1 | 270 Thousand USD | -77.42% |
2019 FY | 1.66 Million USD | -68.7% |
2019 Q4 | 563 Thousand USD | 27.66% |
2019 Q2 | 392 Thousand USD | 45.19% |
2018 Q2 | 1.39 Million USD | 23.56% |
2018 Q4 | 1.19 Million USD | -25.34% |
2018 FY | 5.32 Million USD | 0.0% |
2018 Q1 | 1.12 Million USD | 0.0% |
2018 Q3 | 1.6 Million USD | 14.84% |
2017 Q1 | - USD | 0.0% |
2017 FY | - USD | 0.0% |
2017 Q3 | - USD | 0.0% |
2017 Q4 | - USD | 0.0% |
2017 Q2 | - USD | 0.0% |
2016 FY | - USD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Editas Medicine, Inc. | 78.12 Million USD | 108.513% |
Dynavax Technologies Corporation | 232.28 Million USD | 102.863% |
Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 101.095% |
Perrigo Company plc | 4.65 Billion USD | 100.143% |
Illumina, Inc. | 4.5 Billion USD | 100.148% |
Thermo Fisher Scientific Inc. | 42.85 Billion USD | 100.016% |
Iovance Biotherapeutics, Inc. | 1.18 Million USD | 659.378% |
Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 100.005% |
IQVIA Holdings Inc. | 14.98 Billion USD | 100.044% |
Heron Therapeutics, Inc. | 127.04 Million USD | 105.235% |
Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 100.051% |
Unity Biotechnology, Inc. | - USD | Infinity% |
Waters Corporation | 2.95 Billion USD | 100.225% |
Biogen Inc. | 9.83 Billion USD | 100.068% |
Sangamo Therapeutics, Inc. | 176.23 Million USD | 103.774% |
Evolus, Inc. | 202.08 Million USD | 103.291% |
Adicet Bio, Inc. | - USD | Infinity% |
Cara Therapeutics, Inc. | 20.96 Million USD | 131.72% |
bluebird bio, Inc. | 29.49 Million USD | 122.548% |
Esperion Therapeutics, Inc. | 116.33 Million USD | 105.717% |
FibroGen, Inc. | 147.75 Million USD | 104.501% |
Agilent Technologies, Inc. | 6.83 Billion USD | 100.097% |
Corbus Pharmaceuticals Holdings, Inc. | - USD | Infinity% |
Geron Corporation | 237 Thousand USD | 2906.329% |
Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | 100.364% |
Amicus Therapeutics, Inc. | 399.35 Million USD | 101.665% |
Myriad Genetics, Inc. | 678.4 Million USD | 100.98% |
Viking Therapeutics, Inc. | - USD | Infinity% |
Intellia Therapeutics, Inc. | 36.27 Million USD | 118.335% |
Zoetis Inc. | 8.54 Billion USD | 100.078% |
Abeona Therapeutics Inc. | 3.5 Million USD | 290.029% |
Mettler-Toledo International Inc. | 3.78 Billion USD | 100.176% |
BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 100.275% |
Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 100.067% |
Kala Pharmaceuticals, Inc. | - USD | Infinity% |
Ionis Pharmaceuticals, Inc. | 787.64 Million USD | 100.844% |
Atara Biotherapeutics, Inc. | 8.57 Million USD | 177.581% |
Verastem, Inc. | - USD | Infinity% |
Nektar Therapeutics | 90.12 Million USD | 107.38% |
Axsome Therapeutics, Inc. | 270.6 Million USD | 102.458% |
Aclaris Therapeutics, Inc. | 31.24 Million USD | 121.284% |
Sarepta Therapeutics, Inc. | 1.24 Billion USD | 100.535% |
OPKO Health, Inc. | 863.49 Million USD | 100.77% |
Exelixis, Inc. | 1.83 Billion USD | 100.363% |
Neurocrine Biosciences, Inc. | 1.88 Billion USD | 100.352% |
Corcept Therapeutics Incorporated | 482.37 Million USD | 101.379% |
Anavex Life Sciences Corp. | - USD | Infinity% |
uniQure N.V. | 15.84 Million USD | 141.981% |
Imunon, Inc. | - USD | Infinity% |
Blueprint Medicines Corporation | 249.38 Million USD | 102.667% |
Insmed Incorporated | 305.2 Million USD | 102.179% |
Halozyme Therapeutics, Inc. | 829.25 Million USD | 100.802% |
Agios Pharmaceuticals, Inc. | 26.82 Million USD | 124.796% |
TG Therapeutics, Inc. | 233.66 Million USD | 102.846% |
Incyte Corporation | 3.69 Billion USD | 100.18% |
Emergent BioSolutions Inc. | 1.04 Billion USD | 100.634% |